IMed Group, a leading provider of expert services to the global medical and health technology industry, is pleased to announce the appointment of Parminder Kalle as its new Chief Commercial Officer.
Parminder brings over 20 years of experience across medical devices, in vitro diagnostics (IVDs), Pharma and digital health, combining technical expertise with a proven track record in commercial leadership. In his new role, he will lead IMed Group’s business development and strategic growth initiatives globally.
Parminder joins IMed Group with a mission to accelerate the company’s international growth, build strategic partnerships and enhance the integration of IMed Group’s quality, regulatory and clinical services. His focus is on positioning IMed Group as a trusted global partner that not only delivers compliance but drives value for clients through innovation, insight, and operational agility.
As CCO, Parminder will oversee all aspects of commercial operations, focusing on three core service areas: quality, regulatory and clinical services. Parminder’s approach emphasises a balance of technical excellence and commercial agility, leveraging deep insights into regulatory landscapes, reimbursement pathways and market access strategies to deliver services that are both technically robust and strategically aligned with clients’ business goals. Throughout his career, Parminder has focused on blending technical knowledge with commercial strategy and at IMed, his goal is to ensure the Group’s clients not only meet compliance requirements but can navigate the complexities of regulatory and quality frameworks efficiently turning them into competitive advantage.
“IMed Group is entering an exciting phase of evolution,” said Parminder. “Our strength lies in combining deep regulatory expertise with commercial strategy. My focus is on driving growth through meaningful partnerships and helping our clients adapt quickly to industry change, turning compliance and quality into a platform for long-term success.”
Parminder Kalle’s appointment marks a significant step in IMed Group’s journey to strengthen its market position and broaden its service offering.
This appointment forms part of IMed’s broader plan to scale its global operations and enhance its end-to-end service offering across the Medtech sector.
“Parm brings a rare combination of technical expertise, commercial acumen and international experience” said Leeanne Baker, CEO of IMed Group. “His appointment strengthens our ability to deliver innovative, client-focused solutions across the global life sciences sector. We are confident that his leadership will enable IMed Group to grow further while continuing to provide outstanding support to our clients.”
Article written by Medilink Member.
For more information visit www.imedconsultancy.com
Media relations:
Josephine Ornago
[email protected]
+39 320 2921051
